Fibrates and Statins in the Treatment of Diabetic Retinopathy

被引:9
作者
Ansquer, Jean-Claude [1 ]
Crimet, Dominique [1 ]
Foucher, Christelle [1 ]
机构
[1] Abbott, Clin Dev Labs, F-21121 Daix, France
关键词
Fibrates; statins; diabetic retinopathy; clinical trials; CORONARY-HEART-DISEASE; MICROVASCULAR COMPLICATIONS; RISK-FACTORS; ENDOTHELIAL-CELLS; BLOOD-PRESSURE; MACULAR EDEMA; SERUM-LIPIDS; PROGRESSION; FENOFIBRATE; ASSOCIATION;
D O I
10.2174/138920111794480570
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetic retinopathy (DR) is one of the leading risk factors and causes of blindness worldwide. Tight glucose and blood pressure control has been shown to significantly decrease the risk of development as well as the progression of retinopathy and represents the cornerstone of medical management of DR. The two most threatening complications of DR are diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Photocoagulation is standard treatment for both DME and PDR. However, some patients suffer permanent visual loss despite therapy. Treatment with fibrates first showed reduction in hard exudates, an effect subsequently shown with statins in short term studies, in particular two randomized studies in patients with macular edema. In the FIELD study which pre-specified microvascular outcomes, fenofibrate reduced laser treatment for DME or PDR by 31%: 164 (3.4%) patients on fenofibrate vs. 238 (4.9%) on placebo (p<0.001). In the ophthalmology sub-study of FIELD, the composite exploratory endpoint of 2-step progression of ETDRS retinopathy grade, macular edema or laser treatment was significantly reduced by 34%: 53 (11.1%) patients on fenofibrate vs. 75 (16.1%) on placebo (p=0.022). Conversely, there was no reduction in laser treatment or reduced progression of retinopathy in two large scale studies of statins where cardiovascular events were significantly reduced. Neither class of lipid-lowering drugs consistently improved visual acuity. In the ACCORD-EYE study, the combination of fenofibrate and simvastatin reduced by 40% the rate of progression of diabetic retinopathy compared with simvastatin alone. Other studies are needed to establish the place of lipid lowering drugs in the treatment of macular edema and the prevention of vision loss.
引用
收藏
页码:396 / 405
页数:10
相关论文
共 71 条
  • [1] *ACCORD STUD GROUP, 2010, N ENGL J MED 0629
  • [2] Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
    Aiello, LP
    Bursell, SE
    Clermont, A
    Duh, E
    Ishii, H
    Takagi, C
    Mori, F
    Ciulla, TA
    Ways, K
    Jirousek, M
    Smith, LEH
    King, GL
    [J]. DIABETES, 1997, 46 (09) : 1473 - 1480
  • [3] [Anonymous], 1996, DIABETES, V45, P1289
  • [4] Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
    Ansquer, J. C.
    Foucher, C.
    Aubonnet, P.
    Le Malicot, K.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (05) : 537 - 552
  • [5] Diabetic retinopathy - Seeing beyond glucose-induced microvascular disease
    Antonetti, David A.
    Barber, Alistair J.
    Bronson, Sarah K.
    Freeman, Willard M.
    Gardner, Thomas W.
    Jefferson, Leonard S.
    Kester, Mark
    Kimball, Scot R.
    Krady, J. Kyle
    LaNoue, Kathryn F.
    Norbury, Christopher C.
    Quinn, Patrick G.
    Sandirasegarane, Lakshman
    Simpson, Ian A.
    [J]. DIABETES, 2006, 55 (09) : 2401 - 2411
  • [6] Incidence of coronary heart disease in type 2 diabetic men and women - Impact of microvascular complications, treatment, and geographic location
    Avogaro, Angelo
    Giorda, Carlo
    Maggini, Marina
    Mannucci, Edoardo
    Raschetti, Roberto
    Lombardo, Flavia
    Spila-Alegiani, Stefania
    Turco, Salvatore
    Velussi, Mario
    Ferrannini, Ele
    [J]. DIABETES CARE, 2007, 30 (05) : 1241 - 1247
  • [7] Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
    Banerjee, S
    Denniston, AKO
    Gibson, JM
    Dodson, PM
    [J]. EYE, 2004, 18 (08) : 821 - 825
  • [8] The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
    Barter, P.
    Best, J.
    Colman, P.
    d'Emden, M.
    Davis, T.
    Drury, P.
    Ehnholm, C.
    Glasziou, P.
    Hunt, D.
    Keech, A.
    Kesaniemi, Y. A.
    Laakso, M.
    Scott, R.
    Simes, R. J.
    Sullivan, D.
    Taskinen, M-R
    Whiting, M.
    Ansquer, J-C
    Fraitag, B.
    Anderson, N.
    Hankey, G.
    Hunt, D.
    Lehto, S.
    Mann, S.
    Romo, M.
    Li, L. P.
    Hennekens, C.
    MacMahon, S.
    Pocock, S.
    Tonkin, A.
    Wilhelmsen, L.
    Forder, P.
    Akauola, H.
    Alford, F.
    Barter, P.
    Beinart, I.
    Best, J.
    Bohra, S.
    Boyages, S.
    Colman, P.
    Connor, H.
    Darnell, D.
    Davis, T.
    Davoren, P.
    Lepre, F.
    De Looze, F.
    d'Emden, M.
    Duffield, A.
    Fassett, R.
    Flack, J.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2004, 3 (1)
  • [9] A multifocal electroretinogram model predicting the development of diabetic retinopathy
    Bearse, Marcus A., Jr.
    Adams, Anthony J.
    Han, Ying
    Schneck, Marilyn E.
    Ng, Jason
    Bronson-Castain, Kevin
    Barez, Shirin
    [J]. PROGRESS IN RETINAL AND EYE RESEARCH, 2006, 25 (05) : 425 - 448
  • [10] The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes - Results from Metascreen, a multicenter diabetes clinic-based survey
    Bonadonna, Riccarcdo C.
    Cucinotta, Domenico
    Fedele, Domenico
    Riccardi, Gabriele
    Tiengo, Antonio
    [J]. DIABETES CARE, 2006, 29 (12) : 2701 - 2707